UBS Cuts Rapport Therapeutics Price Target to $64 From $71, Maintains Buy Rating
Rapport Therapeutics has an average rating of buy, according to MT Newswires.
Related stories
Anheuser-Busch Shares Hit 7-year High
Anheuser-Busch shares increased to 76.32 EUR, the highest since October 2019. Over the past 4 weeks, Anheuser-Busch gained 12.82%, and in the last 12 months, it increased 39.96%.
L impact | EQUITY | Nov 05, 2026, 03:51 PM UTC
MNTN Stock Down More Than 50% After Sales Force Disruption and Reduced Outlook
MNTN shares are reported down more than 50% following a sales force disruption and reduced financial outlook.
M impact | EQUITY | Nov 05, 2026, 03:45 PM UTC
Truelink Capital Acquires CSG Creative for GES Platform
Truelink Capital said it acquired CSG Creative, an association marketing and creative agency, to expand its GES platform.
M impact | EQUITY | Nov 05, 2026, 03:45 PM UTC
ScanSource Shares Fall 11.5% After Fiscal Q1 Earnings Miss
ScanSource shares were down 11.5% after the company reported lower fiscal first-quarter non-GAAP earnings that missed estimates.
M impact | EQUITY | Nov 05, 2026, 03:44 PM UTC
N-able Shares Rise 2.7% After Q3 Results Top Estimates
N-able shares rose 2.7% in Thursday trading after its third-quarter results topped estimates.
M impact | EQUITY | Nov 05, 2026, 03:44 PM UTC
Trading Resumes in MindBio Therapeutics
Trading resumed in MindBio Therapeutics Corp. on the CSE.
L impact | EQUITY | Nov 05, 2026, 03:44 PM UTC